Evolent Health Q3 revenue beats expectations

Evolent Health

06/11/2025 21:18

Overview

Evolent Health Q3 2025 revenue beats analyst expectations

Company announces over $500 mln in new annualized revenue for 2026

Outlook

Evolent expects Q4 2025 revenue between $462 mln and $472 mln

Company anticipates 2025 full-year revenue of $1.87 bln to $1.88 bln

Evolent forecasts prelim 2026 revenue to reach $2.5 bln

Result Drivers

NEW CONTRACTS - Evolent signed two new revenue agreements, totaling thirteen for the year, contributing to expected 2026 revenue growth

PRODUCT INNOVATIONS - Innovations in member navigation and Oncology Care Partners are driving growth, per CEO Seth Blackley

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$479.53 mln
$467.50 mln (14 Analysts)
Q3 Net Income
-$26.93 mln
Q3 Adjusted EBITDA
$38.96 mln
Q3 Adjusted EBITDA Margin
8.10%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Evolent Health Inc is $15.50, about 59% above its November 5 closing price of $6.35

The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 30 three months ago

Press Release: ID:nPn1LQBfwa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)